Tearsheet
EHC Home Investment Highlights Valuation, Metrics & Events Price Chart Why The Stock Moved Return vs. Risk About EHC Interactive Breakdown Better Bets vs. EHC Latest Trefis Analyses Trade Ideas More From Trefis Peer Comparisons FDIC Bank Data FDA Approved Drugs Data Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Forward Guidance Insider Activity Trade Sentinel Industry Resource Links External Quote Links

Encompass Health (EHC)

Market Price (4/13/2026): $107.27 | Market Cap: $10.8 Bil
Sector: Health Care | Industry: Health Care Facilities

Encompass Health (EHC)

Market Price (4/13/2026): $107.27
Market Cap: $10.8 Bil
Sector: Health Care
Industry: Health Care Facilities

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0

Attractive yield
Total YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 5.9%

Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 20%

Low stock price volatility
Vol 12M is 29%

Megatrend and thematic drivers
Megatrends include Aging Population & Chronic Disease, and Digital Health & Telemedicine. Themes include Geriatric Care, Remote Patient Monitoring, Show more.

Weak multi-year price returns
2Y Excs Rtn is -0.6%

Key risks
EHC key risks include the cascading fallout from a major exposé on systemic patient safety failures, Show more.

0 Attractive yield
Total YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 5.9%
1 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 20%
2 Low stock price volatility
Vol 12M is 29%
3 Megatrend and thematic drivers
Megatrends include Aging Population & Chronic Disease, and Digital Health & Telemedicine. Themes include Geriatric Care, Remote Patient Monitoring, Show more.
4 Weak multi-year price returns
2Y Excs Rtn is -0.6%
5 Key risks
EHC key risks include the cascading fallout from a major exposé on systemic patient safety failures, Show more.

Valuation, Metrics & Events

Price Chart

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Encompass Health (EHC) stock has remained largely at the same level since 12/31/2025 because of the following key factors:

1. Positive Fourth Quarter 2025 Earnings and 2026 Guidance.

Encompass Health reported strong financial results for the fourth quarter of 2025 on February 5, 2026, with an Adjusted EPS of $1.46, exceeding analyst consensus estimates of $1.29 by $0.17. Quarterly revenue also rose 9.9% year-over-year to $3.09 billion, surpassing the consensus estimate. The company issued 2026 guidance targeting net operating revenue of $6,365 million to $6,465 million and adjusted EPS of $5.81 to $6.10. This positive financial performance and outlook provided fundamental support for the stock, preventing a significant downturn.

2. Persistent Healthcare Sector Headwinds.

Despite company-specific strengths, the broader healthcare sector faced ongoing challenges that likely limited sustained upward momentum for Encompass Health. Industry reports projected a shortage of over 96,000 full-time equivalent physicians in the U.S. in 2026, alongside general rising operating costs, which can squeeze profit margins. These macroeconomic and industry-specific pressures tempered investor enthusiasm and contributed to the stock remaining within a relatively stable range.

Show more

Stock Movement Drivers

Fundamental Drivers

The 1.4% change in EHC stock from 12/31/2025 to 4/12/2026 was primarily driven by a 2.4% change in the company's Total Revenues ($ Mil).
(LTM values as of)123120254122026Change
Stock Price ($)105.74107.251.4%
Change Contribution By: 
Total Revenues ($ Mil)5,7965,9352.4%
Net Income Margin (%)9.3%9.5%2.2%
P/E Multiple19.619.0-3.1%
Shares Outstanding (Mil)1001000.0%
Cumulative Contribution1.4%

LTM = Last Twelve Months as of date shown

Market Drivers

12/31/2025 to 4/12/2026
ReturnCorrelation
EHC1.4% 
Market (SPY)-5.4%30.6%
Sector (XLV)-4.8%23.8%

Fundamental Drivers

The -15.1% change in EHC stock from 9/30/2025 to 4/12/2026 was primarily driven by a -21.7% change in the company's P/E Multiple.
(LTM values as of)93020254122026Change
Stock Price ($)126.35107.25-15.1%
Change Contribution By: 
Total Revenues ($ Mil)5,6695,9354.7%
Net Income Margin (%)9.2%9.5%3.5%
P/E Multiple24.319.0-21.7%
Shares Outstanding (Mil)1011000.1%
Cumulative Contribution-15.1%

LTM = Last Twelve Months as of date shown

Market Drivers

9/30/2025 to 4/12/2026
ReturnCorrelation
EHC-15.1% 
Market (SPY)-2.9%22.2%
Sector (XLV)6.3%20.6%

Fundamental Drivers

The 6.8% change in EHC stock from 3/31/2025 to 4/12/2026 was primarily driven by a 12.5% change in the company's Net Income Margin (%).
(LTM values as of)33120254122026Change
Stock Price ($)100.44107.256.8%
Change Contribution By: 
Total Revenues ($ Mil)5,3735,93510.5%
Net Income Margin (%)8.5%9.5%12.5%
P/E Multiple22.019.0-13.5%
Shares Outstanding (Mil)100100-0.6%
Cumulative Contribution6.8%

LTM = Last Twelve Months as of date shown

Market Drivers

3/31/2025 to 4/12/2026
ReturnCorrelation
EHC6.8% 
Market (SPY)16.3%34.1%
Sector (XLV)2.3%30.5%

Fundamental Drivers

The 102.7% change in EHC stock from 3/31/2023 to 4/12/2026 was primarily driven by a 53.1% change in the company's Net Income Margin (%).
(LTM values as of)33120234122026Change
Stock Price ($)52.91107.25102.7%
Change Contribution By: 
Total Revenues ($ Mil)4,3495,93536.5%
Net Income Margin (%)6.2%9.5%53.1%
P/E Multiple19.419.0-1.7%
Shares Outstanding (Mil)99100-1.3%
Cumulative Contribution102.7%

LTM = Last Twelve Months as of date shown

Market Drivers

3/31/2023 to 4/12/2026
ReturnCorrelation
EHC102.7% 
Market (SPY)63.3%31.4%
Sector (XLV)19.1%34.2%

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
EHC Return-20%17%13%39%16%2%74%
Peers Return31%-16%12%26%22%13%112%
S&P 500 Return27%-19%24%23%16%-0%82%

Monthly Win Rates [3]
EHC Win Rate50%50%50%83%75%50% 
Peers Win Rate62%43%50%55%60%60% 
S&P 500 Win Rate75%42%67%75%67%50% 

Max Drawdowns [4]
EHC Max Drawdown-31%-17%-14%0%-1%-11% 
Peers Max Drawdown-7%-36%-16%-7%-18%-6% 
S&P 500 Max Drawdown-1%-25%-1%-2%-15%-7% 

[1] Cumulative total returns since the beginning of 2021
[2] Peers: SEM, THC, UHS, ENSG, EHAB. See EHC Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 4/10/2026 (YTD)

How Low Can It Go

Unique KeyEventEHCS&P 500
2022 Inflation Shock2022 Inflation Shock  
2022 Inflation Shock% Loss% Loss-39.1%-25.4%
2022 Inflation Shock% Gain to Breakeven% Gain to Breakeven64.2%34.1%
2022 Inflation ShockTime to BreakevenTime to Breakeven408 days464 days
2020 Covid Pandemic2020 Covid Pandemic  
2020 Covid Pandemic% Loss% Loss-39.5%-33.9%
2020 Covid Pandemic% Gain to Breakeven% Gain to Breakeven65.4%51.3%
2020 Covid PandemicTime to BreakevenTime to Breakeven246 days148 days
2018 Correction2018 Correction  
2018 Correction% Loss% Loss-29.9%-19.8%
2018 Correction% Gain to Breakeven% Gain to Breakeven42.7%24.7%
2018 CorrectionTime to BreakevenTime to Breakeven302 days120 days
2008 Global Financial Crisis2008 Global Financial Crisis  
2008 Global Financial Crisis% Loss% Loss-73.6%-56.8%
2008 Global Financial Crisis% Gain to Breakeven% Gain to Breakeven278.4%131.3%
2008 Global Financial CrisisTime to BreakevenTime to Breakeven762 days1,480 days

Compare to SEM, THC, UHS, ENSG, EHAB

In The Past

Encompass Health's stock fell -39.1% during the 2022 Inflation Shock from a high on 4/23/2021. A -39.1% loss requires a 64.2% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Encompass Health (EHC)

Encompass Health Corporation provides facility-based and home-based post-acute healthcare services in the United States. The company operates in two segments, Inpatient Rehabilitation, and Home Health and Hospice. The Inpatient Rehabilitation segment provides specialized rehabilitative treatment on an inpatient and outpatient basis to patients who are recovering from conditions, such as stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations. The Home Health and Hospice segment provides home health and hospice services primarily in the Southeast and Texas. Its home health services include a range of Medicare-certified home nursing services to adult patients in need of care comprising skilled nursing, medical social work, and home health aide services, as well as physical, occupational, speech therapy, and others. This segment's hospice services comprise in-home services to terminally ill patients and their families. As of April 11, 2022, it operated 147 hospitals, 251 home health locations, and 96 hospice locations in 42 states and Puerto Rico. The company was formerly known as HealthSouth Corporation and changed its name to Encompass Health Corporation in January 2018. Encompass Health Corporation was founded in 1983 and is based in Birmingham, Alabama.

AI Analysis | Feedback

Analogies for Encompass Health (EHC):

  • Like HCA Healthcare for specialized recovery and at-home care.

AI Analysis | Feedback

  • Inpatient Rehabilitation Services: Specialized medical rehabilitation programs offered on an inpatient and outpatient basis for patients recovering from various complex conditions and injuries.
  • Home Health Services: A range of Medicare-certified home nursing and therapy services provided to adult patients in their homes.
  • Hospice Services: In-home care and support services designed for terminally ill patients and their families.

AI Analysis | Feedback

Encompass Health (EHC) Major Customers

Encompass Health (EHC) primarily serves individual patients directly, providing specialized post-acute healthcare services. The company does not sell its services to other companies.

Its major customer categories include:

  • Patients in Inpatient Rehabilitation: Individuals recovering from serious medical events or conditions such as stroke, other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations, who require intensive rehabilitative treatment.
  • Adult Patients Requiring Home Health Services: Adults in need of skilled nursing, medical social work, home health aide services, and various therapies (physical, occupational, speech) in a home setting.
  • Terminally Ill Patients and Their Families: Individuals receiving in-home hospice services for end-of-life care, along with support for their families.

AI Analysis | Feedback

null

AI Analysis | Feedback

```html

Mark J. Tarr, President and Chief Executive Officer

Mark Tarr has served as President and Chief Executive Officer for Encompass Health since December 29, 2016. He joined Encompass Health in 1993, holding various management positions, including Executive Vice President and Chief Operating Officer from 2011-2016, Executive Vice President of Operations since August 1, 2007, and President of the company's inpatient division since September 2004. Prior to his time at Encompass Health, Tarr held administrative positions at Tenet Healthcare and Charter Medical, and an early career role at Georgia-Pacific.

Douglas E. Coltharp, Executive Vice President and Chief Financial Officer

Douglas E. Coltharp was named Chief Financial Officer of Encompass Health on May 6, 2010. Before joining Encompass Health, Coltharp served as a partner at Arlington Capital Advisors and Arlington Investment Partners, LLC, which is described as a boutique investment banking and private equity firm. He also spent 11 years as Executive Vice President and Chief Financial Officer for Saks Inc., a Fortune 1000 national retailer, where he was responsible for recapitalizing the company and guiding it through a series of acquisitions and organic growth strategies. Coltharp began his career in 1987 at NationsBank, N.A. (now part of Bank of America), rising to Senior Vice President and head of Southeast Corporate Banking, where he advised Fortune 1000 companies on capital raising. He serves on the board of Under Armour, Inc.

Pat Tuer, Executive Vice President and Chief Operating Officer

Pat Tuer assumed the position of Executive Vice President and Chief Operating Officer in April 2025. He previously served as group president of Encompass Health's Northeast and MidAtlantic regions since August 2023, and as president of the company's Northeast region since March 2021. Prior to Encompass Health, Tuer worked for Select Medical for more than four years, where he held roles including regional vice president and chief executive officer for long-term acute care hospitals. Earlier in his career, he held various leadership roles at Community Health Systems.

Patrick Darby, Executive Vice President, General Counsel and Corporate Secretary

Patrick Darby was named Executive Vice President, General Counsel and Corporate Secretary of Encompass Health in February 2016. Before joining the company, Darby was a partner for 25 years at the law firm of Bradley Arant Boult Cummings LLP in Birmingham, Alabama, specializing in corporate restructuring. He clerked on the United States Circuit Court of Appeals for the Second Circuit and is a Fellow in the American College of Bankruptcy.

Dr. Elissa Charbonneau, Chief Medical Officer

Dr. Elissa Charbonneau was appointed Chief Medical Officer of Encompass Health in June 2015. Previously, she served as the company's Vice President of Medical Services. From 2001 to early 2015, Dr. Charbonneau was Medical Director at New England Rehabilitation Hospital of Portland, a joint venture of Maine Medical Center and Encompass Health, where she had been a staff physician since 1992.

```

AI Analysis | Feedback

Here are the key risks to Encompass Health (EHC):

  1. Regulatory and Reimbursement Risks: Encompass Health's operations are highly susceptible to the complex and evolving regulatory environment, particularly changes in Medicare payment systems and reimbursement policies. Approximately 60% of the company's revenue is tied to Medicare and Medicaid, making it vulnerable to shifts in government healthcare policy, payment cuts, and heightened scrutiny from the Centers for Medicare & Medicaid Services (CMS). The rapid transition to Medicare Advantage plans poses a significant risk, as these plans often implement aggressive prior authorization practices and tighter admission criteria, potentially redirecting patients to lower-cost care settings and impacting Encompass Health's inpatient rehabilitation facility (IRF) utilization. The company faces ongoing audit risks and potential penalties related to compliance, billing practices, and quality-of-care issues.
  2. Patient Safety, Quality of Care, and Associated Litigation/Reputational Risks: Encompass Health faces significant risks related to maintaining a consistently high quality of patient care. Reports, including a high-profile New York Times article, have raised concerns about patient safety and performance at some of its rehabilitation hospitals, citing serious incidents of patient harm, below-average performance on key safety measures like preventable readmissions, and even patient deaths. Such issues can lead to increased regulatory scrutiny, potential litigation (including class-action lawsuits alleging misleading disclosures), and damage to the company's reputation, ultimately impacting patient volumes and investor confidence.
  3. Workforce Shortages and Increased Labor Costs: The broader healthcare sector is experiencing a significant shortage of clinical personnel, which poses a direct challenge to Encompass Health. This can necessitate increased reliance on contract labor and premium pay programs, leading to higher operational costs and potential disruptions in service quality. Persistent labor shortages can also constrain the company's growth initiatives and pressure profit margins.

AI Analysis | Feedback

The emergence of hospital-at-home programs and other intensive home-based care models poses a clear emerging threat to Encompass Health's inpatient rehabilitation segment. These programs leverage technology and coordinated care to deliver facility-level medical and rehabilitative services in a patient's home, offering a potentially more convenient and cost-effective alternative to traditional inpatient rehabilitation facilities for a growing segment of patients.

AI Analysis | Feedback

```html

For Encompass Health Corporation (EHC), the addressable markets for their main products and services in the United States are as follows:

  • Inpatient Rehabilitation: The U.S. medical rehabilitation services market, which includes both inpatient and outpatient settings, generated an estimated revenue of approximately USD 97.25 billion in 2024. This market is projected to grow to about USD 137.11 billion by 2030. Another estimate for the broader rehabilitation industry projects a market size of USD 49.9 billion by 2024.
  • Home Health Services: The U.S. home healthcare market size was estimated at approximately USD 162.35 billion in 2024 and is expected to reach about USD 381.40 billion by 2033.
  • Hospice Services: The U.S. hospice market was estimated at approximately USD 29.92 billion in 2024 and is projected to reach about USD 39.09 billion by 2030.
```

AI Analysis | Feedback

Encompass Health (EHC) is expected to drive future revenue growth over the next 2-3 years through several key strategies and market trends:
  1. Expansion of Inpatient Rehabilitation Hospitals and Capacity Additions: A primary driver of revenue growth for Encompass Health is its aggressive strategy of building new inpatient rehabilitation hospitals (de novo projects) and expanding bed capacity in existing facilities. The company plans to open between 6 and 10 new hospitals annually through 2027 and add 80 to 120 beds to existing hospitals each year. This expansion aims to meet the underserved and growing demand for inpatient rehabilitation services. For example, plans for new 50-bed hospitals in Norristown, Pennsylvania, and San Antonio, Texas, are expected to open in 2026, and in Wesley Chapel, Florida, and Apollo Beach, Florida, by 2027. In 2025, Encompass Health added 517 beds through its investments in capacity.
  2. Increased Patient Discharges and Volume Growth: The company consistently reports revenue growth driven by an increase in total patient discharges, stemming from both new facility openings and same-store growth. For example, Q1 2024 revenue growth was primarily driven by a 10% increase in total discharges, including 6.7% same-store growth. In Q4 2025, total discharges grew 5.3% year-over-year, with same-store discharge growth of 3.2%. Analysts project Encompass Health's 2025 revenue to reach approximately $5.9 billion, reflecting continued expansion and market penetration.
  3. Favorable Pricing and Payer Mix, including Medicare Advantage: Encompass Health benefits from increases in net revenue per discharge, attributed in part to a favorable patient mix and high-quality patient outcomes. The company has successfully increased its Medicare Advantage (MA) payer mix, which nearly doubled from just under 9% in 2019 to almost 17% by the end of 2025. Furthermore, their 2026 guidance anticipates a Medicare pricing increase of approximately 3.0% and a Managed Care pricing increase of 2.0% to 3.0%.
  4. Demographic Tailwinds from an Aging Population: A significant underlying driver for Encompass Health's services is the ongoing demographic trend of an aging population. The "Baby Boomer generation" is increasingly requiring post-acute rehabilitation care, creating a sustained and growing demand for the company's specialized services. This demographic shift ensures a predictable long-term demand curve for inpatient rehabilitation.

AI Analysis | Feedback

Capital Allocation Decisions (Last 3-5 Years)

Share Repurchases

  • Encompass Health allocated $160 million towards share repurchases in 2025.
  • The company reported $31.1 million in annual share buybacks in 2024.
  • For the quarter ending September 30, 2025, share buybacks amounted to $24.9 million.

Share Issuance

  • Encompass Health's shares outstanding were 0.102 billion in 2025.
  • Shares outstanding in 2024 were 0.102 billion, a 0.89% increase from 2023.
  • In 2023, shares outstanding were 0.101 billion, a 0.9% increase from 2022.

Outbound Investments

  • On July 1, 2022, Encompass Health completed the spin-off of Enhabit Home Health & Hospice, establishing it as an independent, publicly traded company.

Capital Expenditures

  • Capital expenditures reached $736 million in 2025, with $527 million specifically allocated for growth capital expenditures.
  • For 2026, the company projects approximately $725 million in growth-related capital expenditures.
  • The primary focus of capital expenditures is on expanding capacity by adding 500 to 600 beds annually through new facilities (de novo hospitals) and additions to existing hospitals, alongside investments in hospital-based technologies and IT infrastructure upgrades.

Better Bets vs. Encompass Health (EHC)

Latest Trefis Analyses

TitleDate
0DASHBOARDS 
1Is ... Fall In Encompass Health (EHC) Stock A Buying Opportunity?03/12/2026
2EHC Stock Surges 21% With A 7-day Winning Spree On Strong Q4 Earnings Beat02/12/2026
3EHC Stock Surges 16% With A 6-day Winning Spree On Strong Q4 Earnings Beat02/11/2026
4Encompass Health Stock Pre-Market (+15%): Strong Q4 EPS Beat & Raised FY26 Guidance02/06/2026
5Encompass Health Earnings Notes12/25/2025
6How Low Can Encompass Health Stock Really Go?10/17/2025
7Encompass Health vs Apollo Asset Management: Which Is A Better Investment?08/18/2025
8Encompass Health vs United Therapeutics: Which Is A Better Investment?08/18/2025
9ARTICLES 
10Time To Buy The Dip In Encompass Health Stock?03/12/2026
11Encompass Health Stock Pre-Market (+15%): Strong Q4 EPS Beat & Raised FY26 Guidance02/06/2026
12Encompass Health or HCA Healthcare: Which Stock Has More Upside?01/28/2026
13Mid Cap Stocks Trading At 52-Week High10/01/2025
14Market Movers | Winners: MP, SSII, UUUU | Losers: SLP, NATL, EHC07/16/2025
Title
0DASHBOARDS
1Is ... Fall In Encompass Health (EHC) Stock A Buying Opportunity?
2EHC Stock Surges 21% With A 7-day Winning Spree On Strong Q4 Earnings Beat
3EHC Stock Surges 16% With A 6-day Winning Spree On Strong Q4 Earnings Beat
4Encompass Health Stock Pre-Market (+15%): Strong Q4 EPS Beat & Raised FY26 Guidance
5Encompass Health Earnings Notes
6How Low Can Encompass Health Stock Really Go?
7Encompass Health vs Apollo Asset Management: Which Is A Better Investment?
8Encompass Health vs United Therapeutics: Which Is A Better Investment?
9ARTICLES
10Time To Buy The Dip In Encompass Health Stock?
11Encompass Health Stock Pre-Market (+15%): Strong Q4 EPS Beat & Raised FY26 Guidance
12Encompass Health or HCA Healthcare: Which Stock Has More Upside?
13Mid Cap Stocks Trading At 52-Week High
14Market Movers | Winners: MP, SSII, UUUU | Losers: SLP, NATL, EHC

Trade Ideas

Select ideas related to EHC.

Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
PGNY_3312026_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG03312026PGNYProgynyDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap		0.0%0.0%0.0%
CNC_3272026_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG03272026CNCCenteneDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap		2.3%2.3%-0.6%
OSCR_3272026_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG03272026OSCROscar HealthDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap		3.0%3.0%-2.6%
WAT_3202026_Monopoly_xInd_xCD_Getting_Cheaper03202026WATWatersMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		-0.4%-0.4%-3.3%
GILD_3202026_Quality_Momentum_RoomToRun_10%03202026GILDGilead SciencesQualityQ | Momentum | UpsideQuality Stocks with Momentum and Upside
Buying quality stocks with strong momentum but still having room to run		1.6%1.6%-2.2%
EHC_6302022_Dip_Buyer_ValueBuy06302022EHCEncompass HealthDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		35.2%54.3%0.0%

Recent Active Movers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons

Peers to compare with:

Financials

EHCSEMTHCUHSENSGEHABMedian
NameEncompas.Select M.Tenet He.Universa.Ensign Enhabit  
Mkt Price107.2516.37195.24180.78199.0213.98144.01
Mkt Cap10.82.017.011.211.50.711.0
Rev LTM5,9355,45321,31017,3655,0581,0605,694
Op Inc LTM1,0533363,4391,99442564739
FCF LTM4391172,53082518066310
FCF 3Y Avg3562551,75682418553305
CFO LTM1,1763463,5401,86456471870
CFO 3Y Avg1,0104822,6541,73342957746

Growth & Margins

EHCSEMTHCUHSENSGEHABMedian
NameEncompas.Select M.Tenet He.Universa.Ensign Enhabit  
Rev Chg LTM10.5%5.1%3.1%9.7%18.7%2.4%7.4%
Rev Chg 3Y Avg10.9%5.8%3.6%9.0%18.7%-0.3%7.4%
Rev Chg Q9.9%6.4%8.9%9.1%20.2%4.7%9.0%
QoQ Delta Rev Chg LTM2.4%1.6%2.2%2.2%4.7%1.2%2.2%
Op Mgn LTM17.7%6.2%16.1%11.5%8.4%6.0%9.9%
Op Mgn 3Y Avg16.4%5.6%14.0%10.1%7.9%4.7%9.0%
QoQ Delta Op Mgn LTM0.5%0.7%0.1%0.0%0.1%0.1%0.1%
CFO/Rev LTM19.8%6.4%16.6%10.7%11.2%6.7%10.9%
CFO/Rev 3Y Avg18.7%9.5%12.7%10.9%9.8%5.4%10.3%
FCF/Rev LTM7.4%2.2%11.9%4.7%3.6%6.2%5.5%
FCF/Rev 3Y Avg6.6%5.1%8.4%5.2%4.4%5.0%5.1%

Valuation

EHCSEMTHCUHSENSGEHABMedian
NameEncompas.Select M.Tenet He.Universa.Ensign Enhabit  
Mkt Cap10.82.017.011.211.50.711.0
P/S1.80.40.80.62.30.70.7
P/EBIT10.05.14.75.324.720.17.6
P/E19.013.512.17.533.3-154.412.8
P/CFO9.25.74.86.020.310.07.6
Total Yield5.9%9.0%8.3%13.7%3.1%-0.6%7.1%
Dividend Yield0.7%1.6%0.0%0.5%0.1%0.0%0.3%
FCF Yield 3Y Avg4.0%10.4%15.1%6.9%2.5%11.6%8.6%
D/E0.31.50.80.50.20.70.6
Net D/E0.21.40.60.40.10.60.5

Returns

EHCSEMTHCUHSENSGEHABMedian
NameEncompas.Select M.Tenet He.Universa.Ensign Enhabit  
1M Rtn7.1%0.7%-14.2%-6.0%-5.1%2.6%-2.2%
3M Rtn4.4%8.0%-3.0%-12.6%14.5%40.2%6.2%
6M Rtn-11.9%24.0%3.0%-7.7%13.6%80.4%8.3%
12M Rtn5.7%1.5%57.7%3.5%55.8%80.2%30.7%
3Y Rtn77.2%12.2%204.7%34.5%103.4%3.2%55.9%
1M Excs Rtn6.2%0.4%-17.4%-3.5%-6.0%2.0%-1.5%
3M Excs Rtn3.9%9.2%-2.5%-12.8%14.5%38.7%6.5%
6M Excs Rtn-14.4%15.0%-3.5%-12.7%12.0%69.3%4.2%
12M Excs Rtn-26.5%-31.0%26.6%-32.1%24.3%43.6%-1.1%
3Y Excs Rtn16.3%-46.2%167.5%-23.5%44.8%-60.7%-3.6%

Comparison Analyses

Financials

Segment Financials

Revenue by Segment
$ Mil20252024202320222021
Inpatient4,6944,252   
Outpatient and other10797   
Home Health and Hospice   1,0781,092
Inpatient rehabilitation   3,5663,513
Total4,8014,349 4,6444,605


Price Behavior

Price Behavior
Market Price$107.25 
Market Cap ($ Bil)10.8 
First Trading Date09/13/1989 
Distance from 52W High-15.4% 
   50 Days200 Days
DMA Price$102.99$112.13
DMA Trenddownindeterminate
Distance from DMA4.1%-4.3%
 3M1YR
Volatility32.5%28.4%
Downside Capture0.080.27
Upside Capture56.2345.42
Correlation (SPY)26.4%26.3%
EHC Betas & Captures as of 3/31/2026

 1M2M3M6M1Y3Y
Beta0.900.790.700.440.510.50
Up Beta1.433.162.571.240.590.54
Down Beta-0.690.320.120.180.380.43
Up Capture154%88%44%3%35%29%
Bmk +ve Days7162765139424
Stock +ve Days8182452128392
Down Capture152%36%79%72%68%69%
Bmk -ve Days12233358110323
Stock -ve Days14243974124356

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
Annualized
Return		Annualized
Volatility		Sharpe
Ratio		Correlation
with EHC
EHC10.3%28.7%0.34-
Sector ETF (XLV)12.3%16.8%0.5228.3%
Equity (SPY)31.2%17.3%1.4733.3%
Gold (GLD)60.1%27.8%1.69-0.8%
Commodities (DBC)29.8%16.6%1.583.9%
Real Estate (VNQ)21.3%15.2%1.0732.8%
Bitcoin (BTCUSD)-4.3%43.7%0.028.5%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
Annualized
Return		Annualized
Volatility		Sharpe
Ratio		Correlation
with EHC
EHC11.9%25.7%0.43-
Sector ETF (XLV)6.3%14.6%0.2542.0%
Equity (SPY)11.1%17.0%0.5040.9%
Gold (GLD)22.1%17.8%1.028.4%
Commodities (DBC)11.8%18.8%0.528.8%
Real Estate (VNQ)3.7%18.8%0.1040.4%
Bitcoin (BTCUSD)4.3%56.5%0.309.1%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
Annualized
Return		Annualized
Volatility		Sharpe
Ratio		Correlation
with EHC
EHC15.3%27.3%0.56-
Sector ETF (XLV)9.8%16.5%0.4849.0%
Equity (SPY)13.8%17.9%0.6650.4%
Gold (GLD)14.2%15.9%0.742.8%
Commodities (DBC)8.6%17.6%0.4117.9%
Real Estate (VNQ)5.1%20.7%0.2248.0%
Bitcoin (BTCUSD)67.6%66.9%1.078.3%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date3312026
Short Interest: Shares Quantity3.4 Mil
Short Interest: % Change Since 3152026-4.9%
Average Daily Volume0.9 Mil
Days-to-Cover Short Interest3.9 days
Basic Shares Quantity100.5 Mil
Short % of Basic Shares3.3%

Returns Analyses

Earnings Returns History

Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
2/5/20265.9%12.6%9.1%
10/29/2025-7.0%-8.2%-8.7%
8/4/20254.0%7.3%12.9%
4/24/202511.8%14.3%17.2%
2/6/20251.3%1.6%0.5%
10/28/20247.4%7.7%11.5%
8/5/2024-5.6%-3.1%4.4%
4/24/2024-0.1%0.1%2.1%
...
SUMMARY STATS   
# Positive161815
# Negative869
Median Positive2.7%3.9%9.1%
Median Negative-1.8%-3.9%-6.2%
Max Positive11.8%14.3%28.3%
Max Negative-7.0%-8.2%-8.7%

SEC Filings

Expand for More
Report DateFiling DateFiling
12/31/202502/26/202610-K
09/30/202510/31/202510-Q
06/30/202508/06/202510-Q
03/31/202505/01/202510-Q
12/31/202402/28/202510-K
09/30/202411/01/202410-Q
06/30/202408/06/202410-Q
03/31/202405/02/202410-Q
12/31/202302/28/202410-K
09/30/202311/01/202310-Q
06/30/202308/04/202310-Q
03/31/202305/03/202310-Q
12/31/202202/27/202310-K
09/30/202211/02/202210-Q
06/30/202208/04/202210-Q
03/31/202205/03/202210-Q

Recent Forward Guidance [BETA]

Latest: Q4 2025 Earnings Reported 2/5/2026

Forward GuidanceGuidance Change
MetricLowMidHigh% Chg% DeltaChangePrior
2026 Revenue6.37 Bil6.42 Bil6.46 Bil8.2% Higher NewGuidance: 5.93 Bil for 2025
2026 Adjusted EBITDA1.34 Bil1.36 Bil1.38 Bil9.2% Higher NewGuidance: 1.25 Bil for 2025
2026 Adjusted earnings per share from continuing operations attributable to Encompass Health5.815.966.112.5% Higher NewGuidance: 5.29 for 2025
2026 Interest expense and amortization of debt discounts and fees 120.00 Mil -4.0% Lower NewGuidance: 125.00 Mil for 2025
2026 Amortization of debt-related items 10.00 Mil 0 Same NewGuidance: 10.00 Mil for 2025

Prior: Q3 2025 Earnings Reported 10/29/2025

Forward GuidanceGuidance Change
MetricLowMidHigh% Chg% DeltaChangePrior
2025 Net operating revenue5.91 Bil5.93 Bil5.96 Bil0 AffirmedGuidance: 5.93 Bil for 2025
2025 Adjusted EBITDA1.24 Bil1.25 Bil1.25 Bil0.8% RaisedGuidance: 1.24 Bil for 2025
2025 Adjusted earnings per share from continuing operations attributable to Encompass Health5.225.295.371.2% RaisedGuidance: 5.23 for 2025
2025 Interest expense and amortization of debt discounts and fees 125.00 Mil 0 AffirmedGuidance: 125.00 Mil for 2025
2025 Amortization of debt-related items 10.00 Mil 0 AffirmedGuidance: 10.00 Mil for 2025

Insider Activity

Expand for More
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value		Value of
Held Shares		Form
1Tuer, Patrick WilliamEVP, Chief Operating OfficerDirectSell8272025123.591,020126,0622,329,177Form
2Tarr, Mark JPresident & CEODirectSell5202025121.53118,38414,387,15264,054,570Form
3Charbonneau, Elissa JoyChief Medical OfficerDirectSell5072025116.614,279498,9741,394,429Form
4Darby, John PatrickEVP, Gen Counsel & SecretaryDirectSell4302025114.7910,0001,147,9009,149,911Form
5Coltharp, Douglas EEVP & Chief Financial OfficerDirectSell4302025115.1543,5755,017,5386,947,404Form

Industry Resources

External Quote Links


Prefer one of these to Trefis? Tell us why.